JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $80
Benzinga Newsdesk 19 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $82 to $80.
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $82 to $80.
